Results 101 to 110 of about 13,106 (183)

Distinct Pattern of Atypical Megakaryocytes in VEXAS Syndrome

International Journal of Laboratory Hematology, Volume 48, Issue 4, Page 713-714, August 2026.
Andrew Y. Sung, Jackson W. Douglas, Olga K. Weinberg, Sharon K. Germans, Weina Chen   +4 more
wiley   +1 more source

Breaking through the azacitidine plateau?-venetoclax in high-risk myelodysplastic syndrome. [PDF]

Ann Transl Med
An Y, Karantanos T.
europepmc   +1 more source

Novel treatment strategies in acute myeloid leukemia. [PDF]

Blood Res
Simkhada S, Joshi U, Dhakal P.
europepmc   +1 more source

Management of Acute Myeloid Leukemia in a Dialysis-Dependent Patient: A Case Report, Literature Review, and Therapeutic Considerations. [PDF]

Cureus
Sapkota S, Alshaikhli A, Shah N, Nepal A, Kulkarni A, Bhandari P, Sapkota S, Kenmoe J, Bayya M, Shrotriya S, Sharma S.   +10 more
europepmc   +1 more source

Rosuvastatin enhances the efficacy of venetoclax-azacitidine in older acute myeloid leukemia patients via reducing T-cell exhaustion. [PDF]

Cancer Immunol Immunother
Zhai Y, Yu Y, Bao R, Liu J, Fang J, Lu W, Zhang D, Guo H, Yao Y, Shi J.   +9 more
europepmc   +1 more source

A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma. [PDF]

Blood Adv
Gordon MJ, Miljkovic MD, Milhon P, Lakhotia R, Melani C, Johnson K, Bryant B, Pittaluga S, Jaffe ES, Conlon K, Staudt LM, Wilson WH, Roschewski M, Ng S.   +13 more
europepmc   +1 more source

Azacitidine for MDS and CMML. [PDF]

Haematologica
Martin ES, Patnaik MM.
europepmc   +1 more source

Pyoderma gangrenosum following treatment with azacitidine in a patient with myelodysplastic syndrome. [PDF]

JAAD Case Rep
Dubakula V, Fort C, Pham C, Dubin M.
europepmc   +1 more source

Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting. [PDF]

Exp Hematol Oncol
Ma C, Cui S, Wang J.
europepmc   +1 more source

A narrative review of mutant isocitrate dehydrogenase AML in Japan based on experience with ivosidenib in AGILE. [PDF]

Int J Hematol
Hiramatsu Y, Urata S, Ishikawa T, Yamauchi T.   +3 more
europepmc   +1 more source